Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Skin stripping adequate as bioequivalence determinant in topicals -- draft guidance.

This article was originally published in The Tan Sheet

Executive Summary

SKIN STRIPPING ADEQUATE FOR DERMATOLOGIC BIOEQUIVALENCE STUDIES for most topical drugs, an FDA draft guidance states. "Skin strip-ping," or dermatopharmacokinetics (DPK), "principles should be generally applicable to all topical dermatological drug products including antifungal, antiviral, anti-acne, antibiotic, corticosteroid and vaginally applied drug products," the draft guidance states. The draft, "Topical Dermatological Drug Product NDAs and ANDAs -- In Vivo Bioavailability, Bioequivalence, In Vitro Release and Associated Studies," was published in the Federal Register June 18.
Advertisement

Related Content

Dermatologic bioequivalence
Dermatologic bioequivalence
Dermatologic bioequivalence

Topics

Advertisement
UsernamePublicRestriction

Register

PS088599

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel